TMSP(SH:600671)2019-04-28 16:00Financial Performance - Operating revenue for the period was CNY 75,708,330.55, representing a decline of 16.23% year-on-year[6]. - Net profit attributable to shareholders of the listed company was CNY -1,874,831.33, compared to CNY 20,276,443.21 in the same period last year, indicating a significant loss[6]. - Basic and diluted earnings per share were both CNY -0.02, down from CNY 0.17 in the previous year[6]. - The company reported non-recurring gains and losses totaling CNY 1,429,690.64 for the period[9]. - The company’s weighted average return on net assets was -3.27%, a significant decline from 26.25% in the previous year[6]. - Total revenue for Q1 2019 was ¥75,708,330.55, a decrease of 16.2% compared to ¥90,371,921.11 in Q1 2018[26]. - Net loss for Q1 2019 was ¥1,005,525.92, compared to a net profit of ¥35,324,830.26 in Q1 2018[27]. - Basic and diluted earnings per share for Q1 2019 were both -¥0.02, compared to ¥0.17 in Q1 2018[28]. - The total comprehensive income for Q1 2019 was CNY 132,534.73, compared to a net loss of CNY -2,721,121.03 in the same period last year[29]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 462,642,130.95, a decrease of 0.31% compared to the end of the previous year[6]. - Total current assets amounted to 215.16 million RMB, a slight decrease from 217.23 million RMB at the end of 2018[20]. - Total liabilities as of March 31, 2019, were 372.09 million RMB, slightly down from 372.51 million RMB at the end of 2018[21]. - The company's total equity was recorded at 90.55 million RMB, down from 91.56 million RMB[21]. - Total liabilities rose to ¥220,950,122.28 in Q1 2019, up from ¥182,190,039.00 in Q1 2018, indicating an increase of 21.3%[25]. Cash Flow - Cash flow from operating activities increased by 13.05% to CNY 38,750,738.27 compared to the same period last year[6]. - Cash inflow from operating activities totaled CNY 111,776,527.56, a decrease of 10.7% from CNY 125,243,116.00 in Q1 2018[31]. - Net cash flow from operating activities was CNY 38,750,738.27, an increase of 13.7% compared to CNY 34,276,082.11 in Q1 2018[31]. - Cash outflow from investing activities was CNY 932,586.70, compared to a net inflow of CNY 8,198,076.72 in Q1 2018[31]. - Net cash flow from financing activities was CNY -59,559,194.87, a significant increase in outflow compared to CNY -6,061,952.31 in Q1 2018[32]. - The ending cash and cash equivalents balance for Q1 2019 was CNY 64,813,183.49, down from CNY 77,038,911.32 in Q1 2018[32]. Shareholder Information - The total number of shareholders at the end of the reporting period was 7,680[10]. - The largest shareholder, Changcheng Film and Television Culture Group Co., Ltd., held 27.25% of the shares, totaling 33,181,813 shares[10]. - The second-largest shareholder, Qingdao Huilong Huaze Investment Co., Ltd., held 22.01% of the shares, totaling 26,799,460 shares[10]. Operational Insights - Cash and cash equivalents decreased by 24.87% to ¥65,214,616.16 from the beginning of the year, primarily due to payments for various renovation projects and bank loan repayments[11]. - Accounts receivable increased by 27.91% to ¥72,805,398.80, with accounts receivable specifically rising by 36.43% to ¥71,333,050.40, mainly due to an increase from the subsidiary Huangshan Mint[11]. - Operating costs decreased by 27.82% to ¥43,685,998.91, reflecting a corresponding reduction in costs due to decreased sales revenue[12]. - Sales expenses increased by 39.70% to ¥21,254,664.82, attributed to adjustments in product pricing while maintaining base sales prices[12]. - Non-operating income dropped significantly by 95.88% to ¥1,540,750.64, mainly due to the absence of large subsidies received in the previous year[12]. - The company invested ¥14,000,000 in establishing the Xishuangbanna Great Wall Health Industry Park, holding a 9.33% stake[13]. - The company is currently optimizing the relocation plan for its production facility in Lin'an, which is undergoing demolition, with a total compensation amount of ¥210,918,492.00[14]. - The company is progressing with the consistency evaluation of its main product, Amoxicillin and Clavulanate Potassium Tablets, aiming to complete it by the end of 2021[14].